MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$4,937,046
EPS
-$7.3
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
General and administrative
1,431,482 2,766,269* 1,056,560 1,242,340
Research and development
3,543,723 4,726,130.5* 2,196,828 1,167,045
Total operating expenses
4,975,205 7,492,399.5 3,253,388 2,409,385
Loss from operations
-4,975,205 -7,492,399.5* -3,253,388 -2,409,385
Other expense
-640* --
Interest income
44,270 38,417* 37,023 38,609
Interest expense
6,111 5,778.5* 2,116 4,185
Total other income (expense)
38,159 31,998.5* 34,907 34,424
Net loss
-4,937,046 -7,460,401 -3,218,481 -2,374,961
Basic EPS
-7.3 -16.827 -5.76 -6.42
Diluted EPS
-7.3 -16.827 -5.76 -6.42
Basic Average Shares
676,172 443,369* 558,868 370,127
Diluted Average Shares
676,172 443,369* 558,868 370,127
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income$44,270 Net loss-$4,937,046 Total other income(expense)$38,159 Interest expense$6,111 Loss from operations-$4,975,205 Total operatingexpenses$4,975,205 Research and development$3,543,723 General andadministrative$1,431,482

CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals, Inc. (CNSP)